摘要
Abstract
Objective:To investigate the role of glycoprotein antigen 724(CA724),neuron-specific enolase(NSE)and gastrin-releasing peptide precursor(ProGRP)in the prognostic assessment of chemotherapy in non-small cell lung cancer(NSCLC).Methods:A total of 132 patients with NSCLC who received chemotherapy treatment in the Third People's Hospital of Henan Province from April 2021 to March 2023 were selected as the study subjects.The levels of CA724,NSE and ProGRP were compared in 132 patients with NSCLC before and after chemotherapy.The patients were followed up for 1 year,and the postoperative survival was recorded.According to the survival status during the follow-up period,the patients were divided into survival group and death group.After 2 courses of chemotherapy,the levels of CA724,NSE and ProGRP were compared between the two groups.The serum levels of CA724 7 U/mL,NSE 20 μg/L and ProGRP 46 ng/L were selected as the cut-off values in 132 NSCLC patients to analyze the relationship between the changes of these three indexes and the survival time of patients.Results:Compared with pre-chemotherapy,CA724,NSE,and ProGRP levels were decreased in 132 NSCLC patients after chemotherapy(P＜0.001).The follow-up results showed that 101 of 132 NSCLC patients survived and 31 died.The levels of CA724,NSE,and ProGRP in the death group were significantly higher than those in the survival group(P＜0.001).Patients with high levels of CA724,NSE and ProGRP(CA724 ≥ 7 U/mL,NSE ≥ 20 μg/L,and ProGRP ≥ 46 ng/L),the progression-free survival and overall survival were significantly shorter than those in patients with low level(CA724＜7 U/mL,NSE＜20 μg/L,and ProGRP＜46 ng/L),(P＜0.05).Conclusions:CA724,NSE and ProGRP have a role in the prognostic assessment of chemotherapy in NSCLC patients,and can be used as one of the important indicators for assessing the effect of chemotherapy and predicting the survival time of patients.关键词
非小细胞肺癌/糖蛋白抗原724/神经元特异性烯醇化酶/胃泌素释放肽前体/生存期/预后Key words
Non-small cell lung cancer/Glycoprotein antigen 724/Neuron specific enolase/Gastrin-releasing peptide precursor/Survival period/Prognosis分类
临床医学
